CD274 and neoplasm: Additionally, combining the TOP1 inhibitor irinotecan with PD-1/PD-L1 antibody mildly reduced tumor growth in cancer mouse models (Iwai et al. 2018; McKenzie et al. 2018; Sen et al. 2019a).